Showing results (51-60 of 62) with videos related to
Sort By:
Pageof 7
Drug and Alcohol Dependence|September 28, 2018
The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in ratsC Austin Zamarripa, Shelley R Edwards, Hina N Qureshi, et al.Psychopharmacology|October 25, 2017
Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male ratsMatthew L Lazenka, Megan J Moerke, E Andrew Townsend, et al.Psychopharmacology|August 25, 2021
The kappa-opioid receptor agonist, triazole 1.1, reduces oxycodone self-administration and enhances oxycodone-induced thermal antinociception in male ratsC Austin Zamarripa, Tanya Pareek, Hayley M Schrock, et al.Behavioural Pharmacology|August 18, 2020
The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone's conditioned rewarding effects in male ratsC Austin Zamarripa, Tilak R Patel, B Cole Williams, et al.Comparative Medicine|January 31, 2019
Ketamine Tolerance in Sprague-Dawley Rats after Chronic Administration of Ketamine, Morphine, or CocaineSamantha A Gerb, Jemma E Cook, Alexandria E Gochenauer, et al.Human Brain Mapping|February 23, 2018
A comparison of manual tracing and FreeSurfer for estimating hippocampal volume over the adult lifespanMike F Schmidt, Judd M Storrs, Kevin B Freeman, et al.Journal of the American Geriatrics Society|August 24, 2016
Associations Between Serum Inflammatory Markers and Hippocampal Volume in a Community SampleMike F Schmidt, Kevin B Freeman, Beverly G Windham, et al.Psychopharmacology|September 27, 2024
Comparison of the reinforcing, antinociceptive, and respiratory depressant effects of prototypical and G-protein biased mu-opioid receptor agonists in male and female Sprague-Dawley ratsC Austin Zamarripa, Tanya Pareek, Loc M Pham, et al.Journal of Psychopharmacology (Oxford, England)|November 4, 2025
Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendationsJack E Henningfield, Sandra D Comer, Matthew L Banks, et al.Translational Psychiatry|April 17, 2026
Cross-Species evidence for hippocampal CACNA1C as a therapeutic target for alcohol use disorderTanya Pareek, Loc M Pham, Sinead M O'Donovan, et al.Pageof 7